Business Context and Reporting Period
This Form 8-K is filed by NanoVibronix, Inc. (trading symbol: NAOV) on April 29, 2020. The report addresses delays in filing the Company's Annual Report on Form 10-K for the year ended December 31, 2019, and its Definitive Proxy Statement. The Company, an emerging growth company incorporated in Delaware, operates primarily from facilities in Israel and relies on third-party manufacturing in China and regulatory bodies in Italy.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on operational disruptions rather than reporting specific financial results for the period.
Material Changes and Operational Impact
- Filing Delays: The Company is utilizing an SEC Order to delay the filing of its 2019 Form 10-K and Proxy Statement due to COVID-19 impacts. The Proxy Statement, including Part III information, is expected to be filed no later than June 15, 2020.
- Workforce Disruption: Due to Israeli government-mandated quarantines, office staff are working remotely. Management has diverted significant time to assess operational impacts, delaying necessary filing tasks.
- Production Halt: The Company's third-party manufacturer in China temporarily shut down for sixty days, causing significant delays in fulfilling sales orders. Production of critical components remains disrupted with uncertain completion dates.
- Regulatory Delays: The regulatory body in Italy responsible for European CE approval has been shut down for over a month, delaying the Company's 2020 CE mark submission.
- Cost Reductions: The financial downturn has compelled the Company to furlough or reduce working hours for much of its operating staff and third-party contractors.
Outlook, Risks, and Contingencies
The Company identifies the coronavirus outbreak as a material risk that may adversely affect its business, operations, and financial position. Specific risks include:
- Supply Chain Interruption: Continued disruption in the supply and delivery of products due to manufacturing shutdowns in China.
- Customer Cash Flow: Clients may encounter cash-flow issues, potentially delaying payments to the Company.
- Audit Delays: Reliance on third-party professionals for financial statement preparation and audits has been hindered by government precautionary measures.
- Market Disruption: The pandemic may divert the medical community's attention and disrupt the marketplace in which the Company operates.
- Capital Raising: The outbreak may hamper the Company's ability to raise additional funds or sell securities.
Management states that the extent of the impact depends on future developments that are highly uncertain and cannot be predicted.
Investor Verification Checklist
- Verify the status of the delayed Form 10-K and Proxy Statement filings by the June 15, 2020 deadline.
- Confirm the resumption of production at the third-party manufacturer in China and the timeline for fulfilling backlogged sales orders.
- Monitor the status of the European CE approval process with the Italian regulatory body.
- Assess the extent of staff furloughs and the impact on the Company's ability to execute its operational plan.
- Review future filings for updates on customer payment delays and the Company's liquidity position.